Dr. Lisa Carey
Claim this profileUniversity of North Carolina at Chapel Hill
Expert in Breast Cancer
Studies Breast cancer
14 reported clinical trials
27 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 positive
ER positive
2Breast Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Lisa Carey is currently running
Ribociclib vs. Palbociclib
for Breast Cancer
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.
Recruiting4 awards Phase 311 criteria
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Recruiting1 award Phase 215 criteria
More about Lisa Carey
Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Lisa Carey has experience with
- Trastuzumab
- Pertuzumab
- Tucatinib
- Sacituzumab Govitecan
- Pembrolizumab
- Paclitaxel
Breakdown of trials Lisa Carey has run
Breast Cancer
Breast cancer
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lisa Carey specialize in?
Lisa Carey focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Lisa Carey currently recruiting for clinical trials?
Yes, Lisa Carey is currently recruiting for 7 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Lisa Carey has studied deeply?
Yes, Lisa Carey has studied treatments such as Trastuzumab, Pertuzumab, Tucatinib.
What is the best way to schedule an appointment with Lisa Carey?
Apply for one of the trials that Lisa Carey is conducting.
What is the office address of Lisa Carey?
The office of Lisa Carey is located at: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the University of North Carolina at Chapel Hill.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.